Proteins and Peptides

27 May 2020

Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers

26 May 2020

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

26 May 2020

Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis

26 May 2020

Biotest achieves significant milestone by completing phase I/III clinical trial with fibrinogen

25 May 2020

Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA

20 May 2020

Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic

20 May 2020

Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

14 May 2020

Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities

14 May 2020

DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study

14 May 2020

Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial

13 May 2020

Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

12 May 2020

Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

8 May 2020

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

7 May 2020

Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin Candidates

5 May 2020

Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab

4 May 2020

Sanofi receives CHMP recommendation for approval of insulin aspart biosimilar

30 April 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

27 April 2020

Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

27 April 2020

FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant

24 April 2020

Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)

21 April 2020

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

20 April 2020

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

20 April 2020

Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin® Proteins to Neutralize SARS-CoV-2 Virus

10 April 2020

Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers

8 April 2020

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

4 April 2020

Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU

2 April 2020

Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment

2 April 2020

Synairgen confirms commencement of dosing in trial of SNG001 in COVID-19

2 April 2020

FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors

2 April 2020

APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

TSLP Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Report Package: Bispecific Antibodies

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins